• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

通过Appl1、Sortilin和Syndecan-1生物标志物对前列腺癌病理学进行重新诠释。

Reinterpretation of prostate cancer pathology by Appl1, Sortilin and Syndecan-1 biomarkers.

作者信息

Logan Jessica M, Martini Carmela, Sorvina Alexandra, Johnson Ian R D, Brooks Robert D, Caruso Maria C, Huzzell Chelsea, Moore Courtney R, Karageorgos Litsa, Butler Lisa M, Tewari Prerna, Prabhakaran Sarita, Hickey Shane M, Klebe Sonja, Samaratunga Hemamali, Delahunt Brett, Moretti Kim, O'Leary John J, Brooks Douglas A, Ung Ben S-Y

机构信息

Clinical and Health Sciences, University of South Australia, Bradley Building, City West Campus, North Terrace, Adelaide, SA, 5000, Australia.

Centre for Cancer Biology, University of South Australia, North Terrace, Adelaide, SA, 5000, Australia.

出版信息

Sci Data. 2024 Aug 8;11(1):852. doi: 10.1038/s41597-024-03696-0.

DOI:10.1038/s41597-024-03696-0
PMID:39117701
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11310308/
Abstract

The diagnosis of prostate cancer using histopathology is reliant on the accurate interpretation of prostate tissue sections. Current standards rely on the assessment of Haematoxylin and Eosin (H&E) staining, which can be difficult to interpret and introduce inter-observer variability. Here, we present a digital pathology atlas and online resource of prostate cancer tissue micrographs for both H&E and the reinterpretation of samples using a novel set of three biomarkers as an interactive tool, where clinicians and scientists can explore high resolution histopathology from various case studies. The digital pathology prostate cancer atlas when used in conjunction with the biomarkers, will assist pathologists to accurately grade prostate cancer tissue samples.

摘要

使用组织病理学诊断前列腺癌依赖于对前列腺组织切片的准确解读。当前标准依赖苏木精和伊红(H&E)染色评估,这可能难以解读且会引入观察者间的差异。在此,我们展示了一个数字病理图谱和前列腺癌组织显微照片的在线资源,涵盖H&E染色以及使用一组新的三种生物标志物对样本进行重新解读,作为一种交互式工具,临床医生和科学家可以通过各种病例研究探索高分辨率组织病理学。数字病理前列腺癌图谱与生物标志物结合使用时,将有助于病理学家准确分级前列腺癌组织样本。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c0a8/11310308/bb563ac1f963/41597_2024_3696_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c0a8/11310308/fe71f00f7f6f/41597_2024_3696_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c0a8/11310308/2d375a364905/41597_2024_3696_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c0a8/11310308/f96d73bcea0a/41597_2024_3696_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c0a8/11310308/898b0cbce5a5/41597_2024_3696_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c0a8/11310308/b388668c311e/41597_2024_3696_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c0a8/11310308/afba930657f1/41597_2024_3696_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c0a8/11310308/bb563ac1f963/41597_2024_3696_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c0a8/11310308/fe71f00f7f6f/41597_2024_3696_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c0a8/11310308/2d375a364905/41597_2024_3696_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c0a8/11310308/f96d73bcea0a/41597_2024_3696_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c0a8/11310308/898b0cbce5a5/41597_2024_3696_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c0a8/11310308/b388668c311e/41597_2024_3696_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c0a8/11310308/afba930657f1/41597_2024_3696_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c0a8/11310308/bb563ac1f963/41597_2024_3696_Fig7_HTML.jpg

相似文献

1
Reinterpretation of prostate cancer pathology by Appl1, Sortilin and Syndecan-1 biomarkers.通过Appl1、Sortilin和Syndecan-1生物标志物对前列腺癌病理学进行重新诠释。
Sci Data. 2024 Aug 8;11(1):852. doi: 10.1038/s41597-024-03696-0.
2
Aberrant protein expression of Appl1, Sortilin and Syndecan-1 during the biological progression of prostate cancer.前列腺癌生物学进展过程中 Appl1、Sortilin 和 Syndecan-1 的异常蛋白表达。
Pathology. 2023 Feb;55(1):40-51. doi: 10.1016/j.pathol.2022.08.001. Epub 2022 Aug 20.
3
Appl1, Sortilin and Syndecan-1 immunohistochemistry on intraductal carcinoma of the prostate provides evidence of retrograde spread.对前列腺导管内癌进行Appl1、Sortilin和Syndecan-1免疫组织化学检测,为逆行扩散提供了证据。
Pathology. 2023 Oct;55(6):792-799. doi: 10.1016/j.pathol.2023.05.004. Epub 2023 Jun 20.
4
Endosomal gene expression: a new indicator for prostate cancer patient prognosis?内体基因表达:前列腺癌患者预后的新指标?
Oncotarget. 2015 Nov 10;6(35):37919-29. doi: 10.18632/oncotarget.6114.
5
A subset of high Gleason grade prostate carcinomas contain a large burden of prostate cancer syndecan-1 positive stromal cells.一部分高Gleason分级的前列腺癌含有大量前列腺癌Syndecan-1阳性基质细胞。
Prostate. 2017 May;77(13):1312-1324. doi: 10.1002/pros.23391. Epub 2017 Jul 26.
6
Soluble syndecan-1 (SDC1) serum level as an independent pre-operative predictor of cancer-specific survival in prostate cancer.可溶性syndecan-1(SDC1)血清水平作为前列腺癌患者癌症特异性生存的独立术前预测指标。
Prostate. 2016 Aug;76(11):977-85. doi: 10.1002/pros.23186. Epub 2016 Apr 7.
7
How often does alpha-methylacyl-CoA-racemase contribute to resolving an atypical diagnosis on prostate needle biopsy beyond that provided by basal cell markers?除了基底细胞标记物所提供的信息外,α-甲基酰基辅酶A消旋酶在解决前列腺穿刺活检非典型诊断方面的频率有多高?
Am J Surg Pathol. 2004 Feb;28(2):239-43. doi: 10.1097/00000478-200402000-00012.
8
Dynamic interplay between sortilin and syndecan-1 contributes to prostate cancer progression.Sortilin 与 syndecan-1 之间的动态相互作用促进了前列腺癌的进展。
Sci Rep. 2023 Aug 18;13(1):13489. doi: 10.1038/s41598-023-40347-7.
9
The expression of syndecan-1 and -2 is associated with Gleason score and epithelial-mesenchymal transition markers, E-cadherin and beta-catenin, in prostate cancer.黏附素-1 和 -2 的表达与前列腺癌的 Gleason 评分以及上皮-间充质转化标志物 E-钙黏蛋白和β-连环蛋白有关。
Urol Oncol. 2010 Sep-Oct;28(5):534-40. doi: 10.1016/j.urolonc.2009.03.018. Epub 2009 May 17.
10
Distinct patterns of biomarker expression for atypical intraductal proliferations in prostate cancer.前列腺癌中非典型导管内增生的生物标志物表达模式不同。
Virchows Arch. 2024 Oct;485(4):723-728. doi: 10.1007/s00428-023-03643-1. Epub 2023 Sep 14.

引用本文的文献

1
Microbial carbon oxidation in seawater below the hypoxic threshold.低氧阈值以下海水中的微生物碳氧化作用
Sci Rep. 2025 Jan 22;15(1):2838. doi: 10.1038/s41598-024-82438-z.

本文引用的文献

1
Distinct patterns of biomarker expression for atypical intraductal proliferations in prostate cancer.前列腺癌中非典型导管内增生的生物标志物表达模式不同。
Virchows Arch. 2024 Oct;485(4):723-728. doi: 10.1007/s00428-023-03643-1. Epub 2023 Sep 14.
2
Dynamic interplay between sortilin and syndecan-1 contributes to prostate cancer progression.Sortilin 与 syndecan-1 之间的动态相互作用促进了前列腺癌的进展。
Sci Rep. 2023 Aug 18;13(1):13489. doi: 10.1038/s41598-023-40347-7.
3
Appl1, Sortilin and Syndecan-1 immunohistochemistry on intraductal carcinoma of the prostate provides evidence of retrograde spread.
对前列腺导管内癌进行Appl1、Sortilin和Syndecan-1免疫组织化学检测,为逆行扩散提供了证据。
Pathology. 2023 Oct;55(6):792-799. doi: 10.1016/j.pathol.2023.05.004. Epub 2023 Jun 20.
4
Prediction of Prostate Cancer Biochemical and Clinical Recurrence Is Improved by IHC-Assisted Grading Using Appl1, Sortilin and Syndecan-1.使用Appl1、Sortilin和Syndecan-1的免疫组化辅助分级可改善前列腺癌生化和临床复发的预测。
Cancers (Basel). 2023 Jun 16;15(12):3215. doi: 10.3390/cancers15123215.
5
Aberrant protein expression of Appl1, Sortilin and Syndecan-1 during the biological progression of prostate cancer.前列腺癌生物学进展过程中 Appl1、Sortilin 和 Syndecan-1 的异常蛋白表达。
Pathology. 2023 Feb;55(1):40-51. doi: 10.1016/j.pathol.2022.08.001. Epub 2022 Aug 20.
6
Benign mimics of prostate cancer.前列腺癌的良性类似物。
Pathology. 2021 Jan;53(1):26-35. doi: 10.1016/j.pathol.2020.08.006. Epub 2020 Oct 16.
7
Identification of areas of grading difficulties in prostate cancer and comparison with artificial intelligence assisted grading.识别前列腺癌分级困难区域,并与人工智能辅助分级进行比较。
Virchows Arch. 2020 Dec;477(6):777-786. doi: 10.1007/s00428-020-02858-w. Epub 2020 Jun 15.
8
The 2019 International Society of Urological Pathology (ISUP) Consensus Conference on Grading of Prostatic Carcinoma.2019 年国际泌尿病理学会(ISUP)前列腺癌分级共识会议。
Am J Surg Pathol. 2020 Aug;44(8):e87-e99. doi: 10.1097/PAS.0000000000001497.
9
Controversial issues in Gleason and International Society of Urological Pathology (ISUP) prostate cancer grading: proposed recommendations for international implementation.在格里森(Gleason)和国际泌尿病理学会(ISUP)前列腺癌分级中存在争议的问题:国际实施的建议。
Pathology. 2019 Aug;51(5):463-473. doi: 10.1016/j.pathol.2019.05.001. Epub 2019 Jul 3.
10
Clinical significance of subtypes of Gleason pattern 4 prostate cancer.Gleason 4级前列腺癌各亚型的临床意义
Transl Androl Urol. 2018 Sep;7(Suppl 4):S477-S483. doi: 10.21037/tau.2018.02.06.